José Valdez Madruga

Author

José Valdez Madruga

Also Known As

Cheng, Andrew K, J. Valdez Madruga, Jose L Casado, Jose Madruga, Jose V Madruga, Jose Valdez Madruga, Jose Valdez Ramalho Madruga, Jose Valdez Ramalho Madruga, José Madruga, José V Madruga

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

Fundação Oswaldo Cruz Instituto Evandro Chagas Universidade de São Paulo Escola Nacional de Saúde Pública San Francisco Department of Public Health

About

José Valdez Madruga is an author at Fundação Oswaldo Cruz specializing in medicine, hiv, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	1.5K
2	Public Health	3	3	309
3	Epidemiology	2	2	562
4	Social Sciences	1	1	206
5	Gender Studies	1	1	206

José Valdez Madruga

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women Raphael J. Landovitz, Deborah Donnell, Meredith E. Clement, New England Journal of Medicine	2021	773
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial Jeffrey L. Lennox, Edwin DeJesus, Adriano Lazzarin, The Lancet Treatment And PreventionAntiviral Drug DevelopmentClinical TrialsAntiviral ResponseAntiviral Therapy	2009	619
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study Pedro Cahn, Anton Pozniak, Horacio Mingrone, The Lancet Treatment And PreventionWeek 48Antiviral Drug DevelopmentAntiviral TherapyDolutegravir Versus Raltegravir	2013	507
Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses Jeffrey L. Lennox, Edwin DeJesus, Daniel S Berger, JAIDS Journal of Acquired Immune Deficiency Syndromes	2010	227
Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study Beatriz Grinsztejn, Brenda Hoagland, Ronaldo I. Moreira, The Lancet HIV Sexual HealthGender IdentitySexual And Reproductive HealthTreatment And PreventionGender Studies	2018	206
The Safety and Efficacy of Tenofovir DF in Combination with Lamivudine and Efavirenz Through 6 Years in Antiretroviral-Naïve HIV-1—Infected Patients Isabel Cassetti, José Valdez Madruga, Jamal Suleiman, HIV Clinical Trials Treatment And PreventionHuman RetrovirusAntiretroviral-naïve Hiv-1—infected PatientsClinical TrialsAntiviral Drug Development	2007	167
High pre‐exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project Brenda Hoagland, Ronaldo I. Moreira, Raquel B. De Boni, Journal of the International AIDS Society	2017	153
Barriers to access to care reported by women living with HIV across 27 countries Margaret Johnson, Xi He, José Valdez Madruga, AIDS Care Health Care DisparityHealthcare ProvisionHealth DisparitiesContraceptionPreventive Medicine	2015	78
Same-day initiation of oral pre-exposure prophylaxis among gay, bisexual, and other cisgender men who have sex with men and transgender women in Brazil, Mexico, and Peru (ImPrEP): a prospective, single-arm, open-label, multicentre implementation study Valdiléa G. Veloso, Carlos Cáceres, Brenda Hoagland, The Lancet HIV	2022	70
Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study Luana M. S. Marins, Thiago S. Torres, Iúri da Costa Leite, PLoS ONE	2019	60

Page 1